BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...Fisher Scientific Inc. to develop companion diagnostics. Illumina is developing the NGS-based pan-cancer companion diagnostic TruSight Tumor 170...
BioCentury | Mar 15, 2018
Tools & Techniques

Shared burden

...with Foundation’s 324-gene panel (R 2 = 0.95), according to Fabrizio, and with Illumina Inc.’s TruSight Tumor 170...
...profiling mutations in cell-free DNA in plasma using a 394-gene panel Illumina Inc. (NASDAQ:ILMN) (A) TruSight Tumor 170...
BioCentury | Jan 13, 2017
Company News

Illumina, IBM deal

...Watson for Genomics to compare variant genetic data produced by TruSight Tumor 170 to published medical literature. TruSight Tumor 170...
BioCentury | Jan 11, 2017
Company News

Illumina rises after introducing new products, deals standardize and simplify genomic data interpretation. Illumina will pair its cancer genome sequencing panel, TruSight Tumor 170...
BioCentury | Nov 17, 2016
Company News

Illumina sales and marketing update

...Illumina launched TruSight Tumor 170 next-generation sequencing solution to evaluate tumor biomarkers. The research use only test runs...
Items per page:
1 - 5 of 5